Vital Capacity in Ultrasound Guided Serratus Plane Block in ED Patients With Multiple Rib Fractures

Vital Capacity in Ultrasound Guided Serratus Plane Block in Emergency Department Patients With Multiple Rib Fractures: A Randomized Controlled Trial

I. Background:

Patients with multiple rib fractures are challenging from both pulmonary and analgesia perspectives. Adequate pain management is essential in prevention of complications secondary to decreased inspiratory volume. Significant morbidity and mortality of rib fractures is secondary to severe pain that limits ribcage movement, decreases inspiratory volumes and causes inadequate cough. Decreased vital capacity predisposes patients to atelectasis, abnormal mucous clearance and pneumonia. The objective of this study is to assess the efficacy of the serratus anterior plane block (SAPB) in improvement of vital capacity in patients with multiple unilateral rib fractures when compared to conventional management with medications. Currently, evidence of efficacy of SAPB in managing pain secondary to multiple rib fractures is limited to case reports and series, none of which evaluate vital capacity.

II. Significance:

The findings of this study may indicate that SAPB is superior to pharmacological management in increasing vital capacity in patients with multiple unilateral rib fractures and suggest SAPB for first line therapy in patients with rib fractures. The findings may decrease the risk of pulmonary complications as well as the use of opiates in management of multiple rib fractures in the Emergency Department especially in patients with numerous comorbidities and contraindications to conventional treatment modalities. This study may support the need for training emergency medicine physicians in bedside SAPB in order to provide the optimal therapy for patient with multiple unilateral rib fractures.

III. Study Objectives:

The primary objectives are to evaluate whether ultrasound guided SAPB results in a greater improvement in percent predicted vital capacity compared to standard therapy with a sham injection. The investigators will also evaluate pain scores and the safety profile of the SAPB procedure compared to those receiving standard analgesia.

IV. Hypothesis:

The primary hypothesis is that SAPB is superior to sham injection in improving the percent of predicted vital capacity. The secondary hypothesis is that SAPB will have greater improvement in pain scores and have a superior safety profile compared to placebo injection.

Study Overview

• Status: Recruiting
• Conditions: Pain
• Intervention / Treatment: Drug: Acetaminophen; Drug: Bupivacain; Drug: Saline

Detailed Description

STUDY DESIGN

This is a single center prospective, randomized, blinded clinical trial with a convenience sample that will be conducted in the Emergency Department of an urban level I trauma center.

A. Identify and enroll all patients coming in to the ED patient with presumed or clinically apparent 2 or more unilateral rib fractures between T3 to T9, with a resting pain score of ≥5. All patients meeting exclusion criteria will be excluded.

B. Randomization procedure:

1. Pharmacy will dispense 30mL of injectate which will be randomized in block of 10 to either the SAPB group (30mL of 0.25% bupivacaine with epinephrine) or sham group (30mL of normal saline).

C. Injection

1. Patient consent will be obtained and time out will be performed on all patients.
2. Patients will be placed on cardiac monitor and placed in lateral decubitus or if unable to turn, they will be supine.
3. Under the usual sterile technique, the serratus anterior muscle overlying the 5th rib at the mid-axillary line will be identified with ultrasound.
4. A spinal needle will be introduced in-plane under ultrasound guidance and advanced until the needle tip is located in the fascial plane just above the serratus anterior muscle. The needle tip will not be advanced unless completely visualized under ultrasound.
5. Normal saline will be injected first to determine correct location of the needle tip. Spreading of fluid along the fascial plane will confirm the correct location of the needle tip.
6. The normal saline will then be switched to the study drug of which 30mL of either normal saline or 0.25% bupivacaine with epinephrine which will then be injected into the fascial plane as described in Blanco et al, and Hetta et al.
7. The study drug will be injected 5mL at a time and the patient will be asked if any symptoms of Local Anesthetic Systemic Toxicity (LAST toxicity) are present (perioral numbness, tinnitus, dizziness).
8. After injection is completed the needle will be withdrawn and patient will remain on the cardiac monitor for another 30 minutes to monitor for symptoms of LAST toxicity (Di Gregorio).
9. This procedure was based on the serratus anterior plane block protocol from Khalil et al.

D. Slow Vital Capacity (SVC) Measurement

1. SVC will be performed using spirometer that has been internally validated
2. SVC will be performed by physicians trained by the respiratory therapy department and who have demonstrated validation compared to respiratory therapist obtained SVC values
3. The patient will be sitting up when performing SVC and a script will be followed as to how to educate and coach the patient on performing appropriate incentive spirometry technique.
4. At least 3 SVC measurements within 150mL of each other are required to qualify for an accurate measurement.
5. The maximum of these 3 SVC values and a corresponding % predicted SVC will be obtained and considered the maximum % predicted SVC.
6. % Predicted SVC will be obtained based on the National Health and Nutrition Examination Survey (NHANES III) calculator through the CDC.

E. Pain scores

1. Subjects will be asked to rate their maximum pain score from 0-10 with resting breathing and with deep breaths.

Design:

A. Potential study patients will be identified through review of the emergency department (ED) electronic board, and ED physicians will also screen for potential study patients. Pain scores are assessed in triage as is standard in the ED.

B. If the patient has pain from presumed or clinically apparent 2 or more unilateral rib fractures between T3 to T9, and he/she has a resting pain score of ≥5 on the Numeric Pain Rating Scale, where 0 is no pain, 5 is moderate pain, and 10 is the worst possible pain upon initial assessment, then he/she will be eligible to participate in the study.

The patient will then be asked to participate if he/she does not have any exclusion criteria.

C. At time of enrollment, the patient will have recorded pain scores, vital signs, and slow vital capacity measured.

D. All patients will then receive as their initial analgesic oral acetaminophen 975 mg followed by morphine sulfate 0.05 mg/kg IV rounded to the nearest milligram.

E. Each patient will then be randomized in either of two arms:

1. Ultrasound guided serratus anterior plane block (SAPB) with 30mL 0.25% bupivacaine with epinephrine.
2. Ultrasound guided serratus anterior plane injection with placebo injection with 30mL of normal saline.

6. Investigators will be blinded to the arm that the patient has been randomized to, as the randomization will occur through the pharmacy dispensing the medication.

7. Using an online randomizer in blocks of 10, the pharmacy will dispense either 30mL of normal saline for the sham group, or 30mL of 0.25% bupivacaine with epinephrine for the nerve block group.

8. All patients will receive either SAPB or placebo injection within an hour of receiving the initial analgesics of acetaminophen and morphine.

9. If the patient still has a pain score ≥5 thirty minutes after the injection, the treating physician will be informed and the patient will be medicated at the treating physician's discretion.

10. The patient will be followed up with up to 24 hours throughout their hospital stay.

Data Collection Procedures:

A. Demographics 1. Age, sex, ethnicity, height B. Past medical history 1. Smoking status (current, prior, never smoker), diabetes, cirrhosis, chronic obstructive pulmonary disease (COPD), asthma, if patient uses home oxygen C. Injury Mechanism

1. Occupant in motor vehicle collision, fall from an elevation, fall down stairs, fall from standing, pedestrian or bicyclist struck by moving vehicle, bike collision or fall from bike while riding, driver or passenger in motorcycle/ATV/motorized scooter collision, assault, unknown mechanism, or other
2. Date and time of injury
3. GCS score
4. Injury Severity Scale D. Imaging

1. Side of rib fractures
2. Number of rib fractures on x-ray and on CT chest
3. Rib fracture location: anterior, lateral, posterior, T1-12
4. Type of imaging showing rib fractures
5. Presence of following: atelectasis, hemothorax, infiltrate (right/left), interstitial edema, pneumothorax, pulmonary contusion E. Medication

1. Any medications type and dose given prior to randomization

F. At Time 0 (time of enrollment):

1. Vital signs
2. Resting pain score from 0-10
3. Deep breath pain score from 0-10

4. Slow Vital Capacity (SVC)

   a. Measured until 3 measurements are within 150mL of each other b. % predicted SVC is measured based on NHANES III Calculator using age, sex, ethnicity and height. If ethnicity not included in calculator will select Caucasian.

   c. Maximum SVC and maximum % predicted SVC

5. Symptoms after injection: sedation, dizziness, dysarthria, nausea, new cardiac rhythm (significant tachycardia or bradycardia, SVT, etc), new significantly increased shortness of breath, perioral numbness, pruritis, seizure, syncope, tinnitus, vomiting G. At Time 30 minutes post injection

1. Vital signs
2. Resting pain score from 0-10
3. Deep breath pain score from 0-10

4. Slow Vital Capacity (SVC)

   1. Measured until 3 measurements are within 150mL of each other
   2. Percentage predicted SVC is measured based on NHANES III Calculator using age, sex, ethnicity and height. If ethnicity not included in calculator will select Caucasian.
   3. Maximum SVC and maximum % predicted SVC
5. Symptoms after injection: sedation, dizziness, dysarthria, nausea, new cardiac rhythm (significant tachycardia or bradycardia, SVT, etc), new significantly increased shortness of breath, perioral numbness, pruritis, seizure, syncope, tinnitus, vomiting H. At Time 60 minutes post injection

1. Vital signs
2. Resting pain score from 0-10
3. Deep breath pain score from 0-10
4. Slow Vital Capacity (SVC)

1. Measured until 3 measurements are within 150mL of each other
2. % predicted SVC is measured based on NHANES III Calculator using age, sex, ethnicity and height. If ethnicity not included in calculator will select Caucasian.
3. Maximum SVC and maximum % predicted SVC

5. Symptoms after injection: sedation, dizziness, dysarthria, nausea, new cardiac rhythm (significant tachycardia or bradycardia, SVT, etc), new significantly increased shortness of breath, perioral numbness, pruritis, seizure, syncope, tinnitus, vomiting I. At Time 3-6 hours post injection

1. Vital signs 2. Resting pain score from 0-10 3. Deep breath pain score from 0-10 4. Slow Vital Capacity (SVC)

1. Measured until 3 measurements are within 150mL of each other
2. % predicted SVC is measured based on NHANES III Calculator using age, sex, ethnicity and height. If ethnicity not included in calculator will select Caucasian.

3. Maximum SVC and maximum % predicted SVC 4. Symptoms after injection: sedation, dizziness, dysarthria, nausea, new cardiac rhythm (significant tachycardia or bradycardia, SVT, etc), new significantly increased shortness of breath, perioral numbness, pruritis, seizure, syncope, tinnitus, vomiting J. At Time 12 hours post injection 1. Vital signs 2. Resting pain score from 0-10 3. Deep breath pain score from 0-10 5. Slow Vital Capacity (SVC)

   1. Measured until 3 measurements are within 150mL of each other
   2. % predicted SVC is measured based on NHANES III Calculator using age, sex, ethnicity and height. If ethnicity not included in calculator will select Caucasian.
   3. Maximum SVC and maximum % predicted SVC

   5. Symptoms after injection: sedation, dizziness, dysarthria, nausea, new cardiac rhythm (significant tachycardia or bradycardia, SVT, etc), new significantly increased shortness of breath, perioral numbness, pruritis, seizure, syncope, tinnitus, vomiting J. On 24 hours post injection

   1. Vital signs
   2. Resting pain score from 0-10
   3. Deep breath pain score from 0-10
   4. Slow Vital Capacity (SVC)

1. Measured until 3 measurements are within 150mL of each other
2. % predicted SVC is measured based on NHANES III Calculator using age, sex, ethnicity and height. If ethnicity not included in calculator will select Caucasian.

3. Maximum SVC and maximum % predicted SVC 5. Symptoms after injection: sedation, dizziness, dysarthria, nausea, new cardiac rhythm (significant tachycardia or bradycardia, SVT, etc), new significantly increased shortness of breath, perioral numbness, pruritis, seizure, syncope, tinnitus, vomiting K. Slow vital capacity

   1. Researchers will be trained on appropriate incentive spirometry technique by the respiratory therapy team and their accuracy will be confirmed 2. Patients will then be instructed to perform SVC, we will get 3 SVC measurements within 150mL of each other and then record the maximum SVC.

   3. Percent predicted vital capacity will be calculating using NHANES III L. Time to first rescue analgesia post injection M. Medications during first 24 hours of hospital stay

   1. 24 hour total morphine milligram equivalent consumption

   1. Calculated based on CDC Morphine Milligram Equivalence (MME) Calculator: https://www.cdc.gov/drugoverdose/prescribing/app.html 2. Any antemetics used after injection within 24 hours after enrollment 3. Time to administration of first rescue analgesia post injection N. Nerve Block performed during inpatient stay

   1. List date/time/type of any additional nerve blocks performed for rib fracture pain after the study injection during the patient's hospital stay

   O. Pulmonary complications:

   1. New O2 requirement, BIPAP or intubation, transfer to ICU for respiratory issue, development of pneumonia, readmission for pulmonary issue, new need for home O2 P. Nerve Block Complications

   1. Development of cellulitis at site of block during hospital stay 2. Pneumothorax occurring within 12 hours of injection Q. Discharge Data

   1. If cellulitis developed at the site of injection during hospital stay
   2. If a pneumothorax on the same side of the injection occurred within 12 hours of block R. Imaging

   1. Videos of the nerve block performance will be recorded in each patient. These images will later be de-identified and reviewed by two independent reviewers not involved in the study to determine visually whether the planar spread of anesthetic was correctly placed or not correctly placed.

• Study Type: Interventional
• Enrollment (Estimated): 90
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Antonios Likourezos, MA, MPH; Phone Number: 718-283-6896; Email: alikourezos@maimonidesmed.org
• Study Contact Backup: Name: Judy Lin, MD; Phone Number: 718-283-6000; Email: julin@maimonidesmed.org

Study Locations

• United States
  • New York
    • Brooklyn, New York, United States, 11219
      • Recruiting
      • Maimonides Medical Center
      • Contact: Antonios Likourezos, MPH; Email: alikourezos@maimonidesmed.org
      • Contact: Lawrence Haines, MD; Email: LHaines@maimonidesmed.org.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 120 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. 18 years or older
2. Presumed/Clinically apparent 2 or more acute unilateral rib fractures between T3-T9
3. Pain Score 5 or greater

Exclusion Criteria:

1. GCS<13
2. Penetrating trauma
3. Pregnant
4. Unable to give consent due to dementia or altered mental status
5. Unable to perform spirometry
6. Requiring immediate surgical intervention
7. Known allergy to amide-type local anesthetics
8. Signs of infection or laceration at injection site
9. Systolic BP <100 mmHg
10. History of chronic pain, chronic use of analgesics
11. History of substance abuse
12. Painful distracting injury (injury causing significant pain that distracts the patient from having reliable scoring of rib fracture pain, i.e. femur fracture, dislocated joint)
13. If patient received any other pain medication besides ketamine prior to the block
14. Only posterior rib fractures present
15. known allergy to acetaminophen
16. Known allergy to morphine sulfate

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: serratus anterior plane block group; The injection of bupivicaine into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle. The skin is cleaned with a sterile solution and the needle is guided right next to the chest muscle where either the bupivicaine injected. After the injection, the needle is taken out.	Drug: Acetaminophen; receive ketamine 0.15 mg/kg IV in 100 mL normal saline over 30 minutes for pain; Drug: Bupivacain; The injection of bupivicaine into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle.
Placebo Comparator: Placeoo injection group; The injection of normal saline into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle. The skin is cleaned with a sterile solution and the needle is guided right next to the chest muscle where saline is injected. After the injection, the needle is taken out.	Drug: Acetaminophen; receive ketamine 0.15 mg/kg IV in 100 mL normal saline over 30 minutes for pain; Drug: Saline; The injection of saline into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Vital Capacity	Vital Capacity will be by a trained respiratory therapist using a spirometer	24 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pain Control	Pain score on 11 point Numeric Rating Scale ranging 0-10 with 0 being no pain, 5 being moderate pain, and 10 being very severe pain	24 hours

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Opiate Usage	The percentage of patients using opiates for pain management	24 hours

Collaborators and Investigators

• Sponsor: Antonios Likourezos
• Investigators: Principal Investigator: Judy Lin, MD, Maimonides Medical Center

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2021
• Primary Completion (Estimated): December 31, 2024
• Study Completion (Estimated): December 31, 2024

Study Registration Dates

• First Submitted: August 25, 2020
• First Submitted That Met QC Criteria: August 25, 2020
• First Posted (Actual): August 28, 2020

Study Record Updates

• Last Update Posted (Actual): January 9, 2024
• Last Update Submitted That Met QC Criteria: January 8, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Keywords: Pain; Pain management; Rib
• Additional Relevant MeSH Terms: Fractures, Bone; Wounds and Injuries; Thoracic Injuries; Rib Fractures; Physiological Effects of Drugs; Central Nervous System Depressants; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Anesthetics; Analgesics, Non-Narcotic; Antipyretics; Anesthetics, Local; Acetaminophen; Bupivacaine
• Other Study ID Numbers: 2019-03-17

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No